NRx Pharmaceuticals, Inc.

8-K Other events Jul 22, 2026 8-K Entered a material agreement; Other events Jun 4, 2026 8-K Other events Jun 2, 2026 10-Q Quarter ended 2026-03-31 May 15, 2026 8-K Director or officer change; Shareholder vote results Mar 24, 2026 10-K Fiscal year ended 2025-12-31 Mar 23, 2026 8-K Other events Feb 17, 2026 8-K Other events Feb 17, 2026 8-K Director or officer change Feb 2, 2026 8-K Delisting notice or listing-rule failure; Regulation FD disclosure; Other events Jan 16, 2026 8-K Regulation FD disclosure Dec 29, 2025 8-K Changed accountants Nov 26, 2025 8-K/A FORM 8-K/A Nov 21, 2025 10-Q Quarter ended 2025-09-30 Nov 14, 2025 8-K Regulation FD disclosure; Other events Oct 23, 2025 8-K Other events Sep 26, 2025 8-K Completed an acquisition or disposition; Regulation FD disclosure Sep 12, 2025 8-K Other events Sep 8, 2025 8-K Entered a material agreement; Results of operations (earnings release); Regulation FD disclosure Aug 18, 2025 10-Q Quarter ended 2025-06-30 Aug 18, 2025 8-K Other events Aug 15, 2025 8-K Other events Jun 9, 2025 8-K Results of operations (earnings release); Regulation FD disclosure May 21, 2025 10-Q Quarter ended 2025-03-31 May 15, 2025 8-K Other events May 13, 2025 10-K/A Fiscal year ended 2024-12-31 Apr 30, 2025 8-K Other events Apr 17, 2025 8-K Results of operations (earnings release); Regulation FD disclosure Mar 21, 2025 10-K Fiscal year ended 2024-12-31 Mar 14, 2025 8-K Entered a material agreement; Other events Feb 3, 2025 8-K Entered a material agreement; Took on a direct financial obligation; Unregistered sale of equity; Other events Jan 29, 2025 8-K Director or officer change; Other events Jan 22, 2025 8-K Director or officer change; Other events Jan 14, 2025 8-K Entered a material agreement; Unregistered sale of equity; Other events Jan 10, 2025 8-K Entered a material agreement; Director or officer change Nov 20, 2024 8-K Results of operations (earnings release); Regulation FD disclosure Nov 15, 2024 10-Q Quarter ended 2024-09-30 Nov 14, 2024 8-K Other events Oct 31, 2024 8-K Entered a material agreement; Took on a direct financial obligation; Unregistered sale of equity Oct 15, 2024 8-K Director or officer change; Shareholder vote results; Regulation FD disclosure Oct 11, 2024